WHO ICTRP trial
An interventional trial assessing the tolerability and safety of GRAZAX® in…
EUCTR2009-014522-41-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-014522-41-DE |
|---|---|
| Public title | An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergy |
| Scientific title | An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergy |
| Primary sponsor | ALK-Abelló A/S |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Denmark;Austria;Germany |
| Conditions | Grass pollen induced rhinoconjunctivitis MedDRA version: 12.0 Level: LLT Classification code 10001728 Term: Allergic rhinoconjunctivitis |
| Interventions | Trade Name: GRAZAX® Pharmaceutical Form: Oral lyophilisate Current Sponsor code: GRAZAX® Concentration unit: SQU Standardised Quality Unit(s) (Deprecated) Concentration type: equal Concentration number: 75,000- |
| Registration date | Oct 21, 2009 |
| Target size | 100 |
| Secondary IDs | GT-22 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: